{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"27.6","upperLimit":"27.6","value":"27.6"},{"groupId":"OG001","lowerLimit":"3.7","upperLimit":"3.7","value":"3.7"},{"groupId":"OG003","lowerLimit":"2.8","upperLimit":"46.3","value":"11.5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"12"}],"units":"Participants"}],"description":"DCB is defined as the time from first observation of response to the time of disease progression.","dispersionType":"Full Range","groups":[{"description":"PCI-32765 420 mg per day\n\nPCI-32765","id":"OG000","title":"Cohort 1"},{"description":"PCI-32765 560 mg per day, 40 mg dexamethasone (oral) once per week\n\nPCI-32765\n\nDexamethasone","id":"OG001","title":"Cohort 2"},{"description":"PCI-32765 840 mg per day\n\nPCI-32765","id":"OG002","title":"Cohort 3"},{"description":"PCI-32765 840 mg per day, 40 mg dexamethasone (oral) once per week\n\nPCI-32765\n\nDexamethasone","id":"OG003","title":"Cohort 4"}],"paramType":"MEDIAN","populationDescription":"Clinical benefit responders.","reportingStatus":"POSTED","timeFrame":"From the date of first study treatment until disease progression per IMWG, up to 60 months","title":"Duration of Clinical Benefit Response (DCB)","type":"SECONDARY","unitOfMeasure":"Months"}